GridAI Technologies Corp. 8-K

What Happened
GridAI Technologies Corp. (f/k/a Entero Therapeutics, Inc.) announced it completed the rescission transactions that unwind the Agreement and Plan of Merger dated March 13, 2024 with ImmunogenX. Under the Rescission Agreement (and an amendment adding shareholder representations, disclosed July 16, 2025), the company transferred all issued and outstanding membership interests in ImmunogenX, LLC to the former shareholders of ImmunogenX, Inc. The parties completed the Transaction on December 31, 2025. After closing, ImmunogenX, LLC is no longer a subsidiary of GridAI and the company holds no interest in Immuno LLC. The filing characterizes the Transaction as a significant disposition.

Key Details

• Rescission Agreement first disclosed on Form 8-K filed March 25, 2025; Amendment adding shareholder accredited-investor reps disclosed July 16, 2025.
• Transaction completed on December 31, 2025 with transfer of all of GridAI’s membership interests in Immuno LLC back to former Immuno shareholders.
• Post-closing: Immuno LLC is no longer a GridAI subsidiary and GridAI holds no interest in Immuno LLC.
• Filing lists related financial statements and exhibits under Item 9.01 (see the 8-K for those exhibits).

Why It Matters
This reverses the 2024 merger/acquisition and removes Immuno LLC from GridAI’s corporate structure, which may affect the company’s reported assets, liabilities and future operating results. The filing labels the step a “significant disposition,” so investors should expect related financial detail in the company’s filings and should review subsequent Form 10-Q/8-K disclosures to understand any material financial impact.